Abstract:Introduction: The distinction between multiple primary lung cancer (MPLC) and intrapulmonary metastasis (IPM) holds clinical significance in staging, therapeutic intervention, and prognosis assessment for multiple lung cancer. Lineage tracing by clinicopathologic features alone remains a clinical challenge; thus, we aimed to develop a multi-omics analysis method delineating spatiotemporal heterogeneity based on tumor genomic profiling. Methods: Between 2012 and 2022, 11 specimens were collected from two patients diagnosed with multiple lung cancer (LU1 and LU2) with synchronous/metachronous tumors. A novel multi-omics analysis method based on whole-exome sequencing, transcriptome sequencing (RNA-Seq), and tumor neoantigen prediction was developed to define the lineage. Traditional clinicopathologic reviews and an imaging-based algorithm were performed to verify the results. Results: Seven tissue biopsies were collected from LU1. The multi-omics analysis method demonstrated that three synchronous tumors observed in 2018 (LU1B/C/D) had strong molecular heterogeneity, various RNA expression and immune microenvironment characteristics, and unique neoantigens. These results suggested that LU1B, LU1C, and LU1D were MPLC, consistent with traditional lineage tracing approaches. The high mutational landscape similarity score (75.1%), similar RNA expression features, and considerable shared neoantigens (n = 241) revealed the IPM relationship between LU1F and LU1G which were two samples detected simultaneously in 2021. Although the multi-omics analysis method aligned with the imaging-based algorithm, pathology and clinicopathologic approaches suggested MPLC owing to different histological types of LU1F/G. Moreover, controversial lineage or misclassification of LU2's synchronous/metachronous samples (LU2B/D and LU2C/E) traced by traditional approaches might be corrected by the multi-omics analysis method. Spatiotemporal heterogeneity profiled by the multi-omics analysis method suggested that LU2D possibly had the same lineage as LU2B (similarity score, 12.9%; shared neoantigens, n = 71); gefitinib treatment and EGFR , TP53 , and RB1 mutations suggested the possibility that LU2E might result from histology transformation of LU2C despite the lack of LU2C biopsy and its histology. By contrast, histological interpretation was indeterminate for LU2D, and LU2E was defined as a primary or progression lesion of LU2C by histological, clinicopathologic, or imaging-based approaches. Conclusion: This novel multi-omics analysis method improves the accuracy of lineage tracing by tracking the spatiotemporal heterogeneity of serial samples. Further validation is required for its clinical application in accurate diagnosis, disease management, and improving prognosis.

Towards the Molecular Era of Discriminating Multiple Lung Cancers

From Morphology to Molecules: Advances in the Distinction of Multiple Primary Lung Cancers From Intrapulmonary Metastases in Non-Small Cell Lung Cancer

Multiple Primary Lung Cancers: A New Challenge in the Era of Precision Medicine.

Using molecular characteristics to distinguish multiple primary lung cancers and intrapulmonary metastases

Optimizing the NGS-based discrimination of multiple lung cancers from the perspective of evolution

Classification of multiple primary lung cancer in patients with multifocal lung cancer: assessment of a machine learning approach using multidimensional genomic data

Emerging Non-Invasive Detection Methodologies For Lung Cancer

[Recent Advances in Diagnosis and Treatment Strategies for Multiple Primary Lung Cancer]

Advances in Diagnosis and Treatment of Multiple Primary Lung Cancer

Multiple primary lung cancer: Updates of clinical management and genomic features

Differential Diagnosis and Treatment Option of Multiple Primary Lung Cancer

Multiple primary lung cancer: Updates and perspectives

Multiple primary lung cancer: a rising challenge

Confronting Synchronous Multiple Primary Lung Cancers: Navigating the Intersection of Challenges and Opportunities

A Comprehensive Algorithm to Distinguish Between MPLC and IPM in Multiple Lung Tumors Patients.

Method for Discriminating Synchronous Multiple Lung Cancers of the Same Histological Type: Mirna Expression Analysis.

Lineage tracing for multiple lung cancer by spatiotemporal heterogeneity using a multi-omics analysis method integrating genomic, transcriptomic, and immune-related features

Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers

Multidirectional characterization of cellular composition and spatial architecture in human multiple primary lung cancers

Diagnosis and management of multiple primary lung cancer

P3.16-053 Genomic Challenges for Lung Cancers with Multiple Pulmonary Sites of Involvement